Tramadol for treatment of neurogenic cough: a retrospective case series

Benjamin J. Rubinstein, Shiv Saidha, John T. SinacoriThe Journal of Laryngology & Otology 2025 · DOI

TL;DR

This retrospective study investigated the effectiveness of tramadol for treating neurogenic cough, a chronic condition often linked to hypersensitivity in the airways. The findings suggest tramadol is a well-tolerated and effective treatment option, with a significant portion of patients experiencing complete or partial relief from their cough.

What Problem Does This Paper Address?

Chronic cough affects a substantial portion of the population, leading to significant morbidity and healthcare costs. While various causes exist, a growing understanding points to neurogenic laryngeal hypersensitivity, or "neurogenic cough," as a key driver in many cases. This condition involves an overactive cough reflex triggered by non-noxious stimuli. Current treatments often involve neuromodulators, medications typically used for pain management, but these can come with significant side effects. The authors sought to explore the efficacy and tolerability of tramadol, an opioid with analgesic and antitussive properties, as a treatment for neurogenic cough, aiming to find a more effective and better-tolerated option.

Methods

This study employed a retrospective chart review of adult patients diagnosed with neurogenic cough (ICD-9 code 786.2; ICD-10 code R05) treated with tramadol at a single tertiary academic medical center. The diagnosis of neurogenic cough was based on a classic history of cough triggered by non-noxious stimuli and cough unexplained by or refractory to standard workups. Patients were included if they were prescribed tramadol and had a follow-up appointment to assess efficacy. Response was categorized as complete (no pathologic coughing) or partial (at least 50% reduction in severity or frequency). Data collected included patient demographics, tramadol dosage and duration, and clinical response documented during follow-up visits. Chi-squared analysis was used to assess differences in response rates across various clinical categories.

Datasets

The study utilized retrospective chart data from 69 patients treated at a single institution between January 2010 and August 2016. No new datasets were introduced.

Key Insights and Ideas

  • Tramadol as a Promising Neuromodulator: The study highlights tramadol's potential as a valuable neuromodulator for neurogenic cough, offering a viable alternative to other medications that may have more significant side effects.
  • Dual Mechanism of Action: Tramadol's multifaceted pharmacological properties (opioid receptor agonism, SNRI activity, muscarinic receptor antagonism) likely contribute to its effectiveness in addressing both the sensory and cough suppression aspects of neurogenic cough.
  • Tolerability and Weaning Potential: The medication was generally well-tolerated, with sedation being the most common side effect. Importantly, a significant proportion of complete responders were successfully weaned off tramadol, suggesting it can be a temporary rather than a lifelong treatment for some.
  • Laryngeal Surgery as a Predictor of Non-Response: A history of laryngeal surgery was found to be a significant predictor of a poorer response to tramadol, suggesting that structural changes or altered nerve pathways in the larynx may influence treatment outcomes.

Key Results

  • Response Rates: Of the 69 patients studied, 38% reported a complete response (CR), 33% reported a partial response (PR), and 29% reported no response (NR).
  • Optimal Dosing: The most frequent successful tramadol dose was 50 mg twice daily.
  • Weaning Success: 50% of complete responders were successfully weaned off tramadol after a mean of 39 weeks of treatment.
  • Side Effects: Sedation was the most common side effect, reported by 10% of patients. Six patients discontinued the medication due to side effects or drug interactions.
  • Predictors of Response: Patients with a history of laryngeal surgery were significantly less likely to respond to tramadol (p = 0.04).
  • Time to Response: The majority of complete responders (80%) were asymptomatic by 16 weeks, with 27% stopping coughing within 4 weeks.

Limitations and Future Work

  • Retrospective Design: The retrospective nature of the study limits the ability to control for confounding variables and relies on documented patient reporting, which may not always be standardized.
  • Lack of Validated Instrument: The absence of a validated instrument for assessing outcomes in this patient population is a limitation.
  • Compliance: The study could not definitively comment on patient compliance with prescribed medications due to its retrospective design.
  • Future Directions: The authors suggest future prospective trials to randomize tramadol against placebo, optimize weaning protocols, and further elucidate the specific central or peripheral effects of tramadol on the cough pathway. They also propose clinical trials to investigate the relative contributions of tramadol's various activities and to develop clinical protocols for determining treatment success and weaning.

Summary updated

Abstract

Tramadol may be effective and is well tolerated in patients with neurogenic cough.
BibTeX
@article{rubinstein2025tramadol,
  author = {Benjamin J. Rubinstein and Shiv Saidha and John T. Sinacori},
  title = {{Tramadol for treatment of neurogenic cough: a retrospective case series}},
  journal = {The Journal of Laryngology \& Otology},
  year = {2025},
  doi = {10.1017/s0022215125103915},
}
Figure